X

Trial Profile

Novel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple Myeloma

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 16 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Belantamab mafodotin (Primary) ; Elotuzumab (Primary)
Indications Multiple myeloma
Focus Adverse reactions

Most Recent Events

04 Jun 2024 Results (As of January 20, 2024, n=12) from phase I part of this trial, presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
13 Nov 2023 Planned End Date changed from 1 Dec 2023 to 1 Dec 2026.
13 Nov 2023 Planned primary completion date changed from 1 Aug 2023 to 1 Jan 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com